PURPOSE: Nicotinic acetylcholine receptors (nAChR) are best known for their role in neurotransmission, but they have recently been demonstrated on vascular endothelial cells. Acetylcholine is their endogenous ligand, but they are also stimulated by nicotine. By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovascularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV). METHODS: The effect of the nonselective nAChR antagonist mecamylamine was tested on human retinal and choroidal endothelial cells in vitro and in a murine model of CNV. RESULTS: Several nAChR isoforms were identified in retinal and choroidal microvascular endothelial cells, and the ability of these cells to form tubules when grown in growth factor-reduced basement membrane matrix and supplemented with VEGF was suppressed by the nAChR antagonist mecamylamine. Supplementation of the drinking water of mice with nicotine increased the size of CNV lesions at Bruch membrane rupture sites, an effect that was blocked by subcutaneous administration of mecamylamine (50 mg/kg/d) by an osmotic pump. In the absence of nicotine, CNV formation was suppressed by the infusion of 50 mg/kg/d mecamylamine or by topical application 0.1 or 1% mecamylamine to the cornea. CONCLUSIONS: These data suggest that endogenous activation of nAChR promotes CNV and that activation of nAChR by nicotine may contribute to the increased incidence of CNV seen in smokers with age-related macular degeneration (AMD). Topically administered mecamylamine could provide an appealing new treatment approach for CNV.
PURPOSE:Nicotinic acetylcholine receptors (nAChR) are best known for their role in neurotransmission, but they have recently been demonstrated on vascular endothelial cells. Acetylcholine is their endogenous ligand, but they are also stimulated by nicotine. By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovascularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV). METHODS: The effect of the nonselective nAChR antagonist mecamylamine was tested on human retinal and choroidal endothelial cells in vitro and in a murine model of CNV. RESULTS: Several nAChR isoforms were identified in retinal and choroidal microvascular endothelial cells, and the ability of these cells to form tubules when grown in growth factor-reduced basement membrane matrix and supplemented with VEGF was suppressed by the nAChR antagonist mecamylamine. Supplementation of the drinking water of mice with nicotine increased the size of CNV lesions at Bruch membrane rupture sites, an effect that was blocked by subcutaneous administration of mecamylamine (50 mg/kg/d) by an osmotic pump. In the absence of nicotine, CNV formation was suppressed by the infusion of 50 mg/kg/d mecamylamine or by topical application 0.1 or 1% mecamylamine to the cornea. CONCLUSIONS: These data suggest that endogenous activation of nAChR promotes CNV and that activation of nAChR by nicotine may contribute to the increased incidence of CNV seen in smokers with age-related macular degeneration (AMD). Topically administered mecamylamine could provide an appealing new treatment approach for CNV.
Authors: Christopher Heeschen; Michael Weis; Alexandra Aicher; Stefanie Dimmeler; John P Cooke Journal: J Clin Invest Date: 2002-08 Impact factor: 14.808
Authors: K Mori; A Ando; P Gehlbach; D Nesbitt; K Takahashi; D Goldsteen; M Penn; C T Chen; K Mori; M Melia; S Phipps; D Moffat; K Brazzell; G Liau; K H Dixon; P A Campochiaro Journal: Am J Pathol Date: 2001-07 Impact factor: 4.307
Authors: W Smith; J Assink; R Klein; P Mitchell; C C Klaver; B E Klein; A Hofman; S Jensen; J J Wang; P T de Jong Journal: Ophthalmology Date: 2001-04 Impact factor: 12.079
Authors: T Tobe; S Ortega; J D Luna; H Ozaki; N Okamoto; N L Derevjanik; S A Vinores; C Basilico; P A Campochiaro Journal: Am J Pathol Date: 1998-11 Impact factor: 4.307
Authors: Ivan J Suñer; Diego G Espinosa-Heidmann; Maria E Marin-Castano; Eleut P Hernandez; Simone Pereira-Simon; Scott W Cousins Journal: Invest Ophthalmol Vis Sci Date: 2004-01 Impact factor: 4.799
Authors: Henry F Edelhauser; Cheryl L Rowe-Rendleman; Michael R Robinson; Daniel G Dawson; Gerald J Chader; Hans E Grossniklaus; Kay D Rittenhouse; Clive G Wilson; David A Weber; Baruch D Kuppermann; Karl G Csaky; Timothy W Olsen; Uday B Kompella; V Michael Holers; Gregory S Hageman; Brian C Gilger; Peter A Campochiaro; Scott M Whitcup; Wai T Wong Journal: Invest Ophthalmol Vis Sci Date: 2010-11 Impact factor: 4.799
Authors: Jan Bucerius; Christoph Manka; Jörn Schmaljohann; Venkatesh Mani; Daniela Gündisch; James H F Rudd; Rolf Bippus; Felix M Mottaghy; Ullrich Wüllner; Zahi A Fayad; Hans-Jürgen Biersack Journal: JACC Cardiovasc Imaging Date: 2012-05
Authors: Takeshi Iwase; Brian C Oveson; Noriyasu Hashida; Raquel Lima e Silva; Jikui Shen; Achim H Krauss; David C Gale; Peter Adamson; Peter A Campochiaro Journal: Invest Ophthalmol Vis Sci Date: 2013-01-21 Impact factor: 4.799
Authors: Peter A Campochiaro; Syed Mahmood Shah; Gulnar Hafiz; Jeffery S Heier; Eugene S Lit; Ingrid Zimmer-Galler; Roomasa Channa; Quan Dong Nguyen; Beena Syed; Diana V Do; Lili Lu; James Monk; John P Cooke; M Ken Kengatharan; Henry H Hsu Journal: Am J Ophthalmol Date: 2010-02-26 Impact factor: 5.258
Authors: Ji Liu; Alice M McGlinn; Alcides Fernandes; Ann H Milam; Christianne E Strang; Margot E Andison; Jon M Lindstrom; Kent T Keyser; Richard A Stone Journal: Invest Ophthalmol Vis Sci Date: 2008-10-24 Impact factor: 4.799
Authors: Jenny C F Wu; Andrzej Chruscinski; Vinicio A De Jesus Perez; Harvir Singh; Maria Pitsiouni; Marlene Rabinovitch; Paul J Utz; John P Cooke Journal: J Cell Biochem Date: 2009-10-01 Impact factor: 4.429